Reinvestment in Research and Development, Facilities and New Business Areas
First written in FY2016. 12 of 33 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2025: 4 of 41 companies on the "Worse" side.
21 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「R&D expenses for the fiscal year were ¥699 million.」
R&D expenses were ¥699.59 million, up from ¥591 million in the previous fiscal year. The policy of reinvesting in R&D and new business areas has expanded in monetary terms. - FY2026-H1Lower R&D spending in the interim periodAnnual report
「The amount spent on R&D activities during the interim accounting period was ¥347 million.」
R&D expenses for the interim period were ¥347 million, down from ¥382 million in the same period of the previous fiscal year. At the same time, it was stated that there had been no material changes in the status of R&D activities, and no change in the policy itself of reinvesting in R&D was disclosed. - FY2025-H1Higher interim-period R&D expensesAnnual report
「The amount spent on R&D activities during the interim accounting period was ¥382 million.」
R&D expenses for the interim accounting period were ¥382 million, up from ¥364 million in the same period of the previous fiscal year. It was stated that there had been no material changes in the status of R&D activities. - FY2024Continued decline in research and development expensesAnnual report
「R&D expenses for the fiscal year were ¥591 million.」
The policy of reinvesting in R&D, manufacturing facilities and new business areas remains ongoing. R&D expenses for the fiscal year were ¥591 million, down from ¥725 million in the previous fiscal year. - FY2024-Q3Continued decline in research and development expensesAnnual report
「The amount spent on R&D activities during the cumulative third-quarter period was ¥406 million.」
R&D expenses were ¥406 million, down from ¥559 million in the same period of the previous fiscal year. It was stated that there had been no material changes in the status of R&D activities, and the reinvestment policy itself remains ongoing. - FY2024-Q2Decline in R&D ExpenditureAnnual report
「The amount spent on R&D activities during the cumulative second-quarter period was ¥233 million.」
R&D expenses for the cumulative second-quarter period were ¥233 million, down from ¥364 million in the same period of the previous fiscal year. It was stated that there had been no material changes in the status of R&D activities, and the reinvestment policy itself remains ongoing. - FY2024-Q1Decline in R&D ExpenditureAnnual report
「The amount spent on R&D activities during the cumulative first-quarter period was ¥119 million.」
R&D expenses were ¥119 million, down from ¥217 million in the same period of the previous fiscal year. It was stated that there had been no material changes in the status of R&D activities, and the policy itself of reinvesting in R&D remains ongoing. - FY2023Decline in R&D ExpenditureAnnual report
「R&D expenses for the fiscal year were ¥725 million.」
R&D expenses were ¥725 million, down from ¥863 million in the previous fiscal year. The policy itself of reinvesting in R&D, manufacturing facilities and new business areas remains ongoing. - FY2023-Q3RestatedAnnual report
「The amount spent on R&D activities during the cumulative third-quarter period was ¥559 million. There were no material changes in the status of the Company's R&D activities during the cumulative third-quarter period.」
R&D expenses for the cumulative third-quarter period were ¥559 million, and it was stated that there had been no material changes in R&D activities. The policy of reinvesting in R&D is ongoing. - FY2023-Q2RestatedAnnual report
「The amount spent on research and development during the cumulative second quarter was ¥364 million. There were no material changes in the status of the company's research and development activities during the cumulative second quarter.」
R&D expenses for the cumulative second-quarter period were ¥364 million, and it was stated that there had been no material changes in R&D activities. The policy of reinvesting in R&D is ongoing. - FY2023-Q1RestatedAnnual report
「The amount spent on research and development during the cumulative first quarter was ¥217 million. There were no material changes in the status of the company's research and development activities during the cumulative first quarter.」
The company spent ¥217 million on research and development and stated that there were no material changes in the status of its research and development activities. It continues its policy of reinvesting in research and development. - FY2022AdvancedAnnual report
「The company's research and development expenses for the fiscal year were ¥863 million.」
Research and development expenses were ¥863.27 million, up from ¥672.93 million in the previous fiscal year. Reinvestment in research and development increased in monetary terms. - FY2022-Q3Increase in Research and Development ExpensesAnnual report
「The amount spent on research and development during the cumulative third quarter was ¥623 million.」
Research and development expenses for the cumulative third quarter were ¥623 million, up from ¥484 million in the same period of the previous year. The company also stated that there were no material changes in the status of its research and development activities. - FY2022-Q2Increase in Research and Development ExpensesAnnual report
「The amount spent on research and development during the cumulative second quarter was ¥377 million.」
Research and development expenses for the cumulative second quarter were ¥377 million, up from ¥314 million in the same period of the previous year. The company also stated that there were no material changes in the status of its research and development activities. - FY2022-Q1Increase in Research and Development ExpensesAnnual report
「The amount spent on research and development during the cumulative first quarter was ¥217 million.」
Research and development expenses were ¥217 million, up from ¥145 million in the same period of the previous year. The company also stated that there were no material changes in the status of its research and development activities. - FY2021AdvancedAnnual report
「The company's research and development expenses for the fiscal year were ¥672 million.」
Regarding its policy of reinvesting in research and development, the company's research and development expenses for the fiscal year were ¥672 million, an increase from ¥552 million in the previous fiscal year. - FY2021-Q3RestatedAnnual report
「The amount spent on research and development during the cumulative third quarter was ¥484 million. There were no material changes in the status of the company's research and development activities during the cumulative third quarter.」
The company reported research and development expenses of ¥484 million for the cumulative third quarter and stated that there were no material changes in the status of its research and development activities. It continues its policy of reinvesting in research and development. - FY2021-Q2RestatedAnnual report
「The amount spent on research and development during the cumulative second quarter was ¥314 million. There were no material changes in the status of the company's research and development activities during the cumulative second quarter.」
The company reported research and development expenses of ¥314 million and stated that there were no material changes in the status of its research and development activities. It continues its policy of reinvesting in research and development. - FY2021-Q1Decline in R&D ExpenditureAnnual report
「The amount spent on research and development during the cumulative first quarter was ¥145 million.」
While stating that there were no material changes in the status of its research and development activities, the company reported research and development expenses of ¥145 million, down from ¥182 million in the same period of the previous year. - FY2020Decline in R&D ExpenditureAnnual report
「The company's research and development expenses for the fiscal year were ¥552 million.」
Research and development expenses were ¥552 million, down from ¥804 million in the previous fiscal year. No change was reported in the policy of continuing research and development. - FY2020-Q3Decline in R&D ExpenditureAnnual report
「The amount spent on research and development during the cumulative third quarter was ¥431 million. There were no material changes in the status of the company's research and development activities during the cumulative third quarter.」
While stating that there were no material changes in the status of its research and development activities, the company reported research and development expenses of ¥431 million, down from ¥598 million in the same period of the previous year. - FY2020-Q2Decline in R&D ExpenditureAnnual report
「The amount spent on research and development during the cumulative second quarter was ¥314 million.」
While stating that there were no material changes in the status of its research and development activities, the company reported research and development expenses of ¥314 million, down from ¥368 million in the same period of the previous year. - FY2020-Q1Decline in R&D ExpenditureAnnual report
「The amount spent on research and development during the cumulative first quarter was ¥182 million. There were no material changes in the status of the company's research and development activities during the cumulative first quarter.」
While stating that there were no material changes in the status of its research and development activities, the company reported research and development expenses of ¥182 million, down from ¥197 million in the same period of the previous year. - FY2019Decline in R&D ExpenditureAnnual report
「The company's research and development expenses for the fiscal year were ¥804 million.」
Research and development expenses were ¥804 million, down from ¥821 million in the previous fiscal year. No change was reported in the research and development policy itself, which emphasizes customer needs and safety. - FY2019-Q3RestatedAnnual report
「The amount spent on research and development during the cumulative third quarter was ¥541 million. There were no material changes in the status of the company's research and development activities during the cumulative third quarter.」
The company reported research and development expenses of ¥541 million for the cumulative third quarter and stated that there were no material changes in the status of its research and development activities. - FY2019-Q1RestatedAnnual report
「The amount spent on research and development during the cumulative first quarter was ¥197 million. There were no material changes in the status of the company's research and development activities during the cumulative first quarter.」
The company states that research and development expenses during the cumulative first quarter were ¥197 million and that there were no material changes in the status of its research and development activities. This reaffirms its policy of reinvesting in research and development. - FY2018AdvancedAnnual report
「The company's research and development expenses for the fiscal year were ¥821 million.」
Regarding its policy of reinvesting in research and development, the company reported research and development expenses of ¥821 million for the fiscal year. This was an increase from ¥593 million in the previous fiscal year, and the company also explained that the increase reflected product development focused on customer needs. - FY2018-Q3RestatedAnnual report
「The amount spent on research and development during the cumulative third quarter was ¥598 million. There were no material changes in the status of the company's research and development activities during the cumulative third quarter.」
The company states that it spent ¥598 million on research and development and that there were no material changes in the status of its research and development activities. This reaffirms its policy of reinvesting in research and development. - FY2018-Q2RestatedAnnual report
「The amount spent on research and development during the cumulative second quarter was ¥386 million. There were no material changes in the status of the company's research and development activities during the cumulative second quarter.」
The company states that it spent ¥386 million on research and development and that there were no material changes in the status of its research and development activities. This reaffirms its policy of reinvesting in research and development. - FY2018-Q1RestatedAnnual report
「The amount spent on research and development during the cumulative first quarter was ¥187 million. There were no material changes in the status of the company's research and development activities during the cumulative first quarter.」
The company states that it spent ¥187 million on research and development and that there were no material changes in the status of its research and development activities. This reaffirms its policy of reinvesting in research and development. - FY2017RestatedAnnual report
「The company plans to invest retained earnings in research and development, manufacturing facilities and new fields, and to return profits to shareholders with the aim of enhancing shareholder value.」
The company has reiterated its policy of investing retained earnings in research and development, manufacturing facilities and new fields, with the aim of enhancing shareholder value. - FY2017-Q3RestatedAnnual report
「The amount spent on research and development during the cumulative third quarter was ¥479 million. There were no material changes in the status of the company's research and development activities during the cumulative third quarter.」
The company states that it spent ¥479 million on research and development, while reporting no material changes in the status of its research and development activities. - FY2016First statedAnnual report
「The company plans to invest retained earnings in research and development, manufacturing facilities and new fields, and to return profits to shareholders with the aim of enhancing shareholder value.」
The company plans to invest retained earnings in research and development, manufacturing facilities and new fields, with the aim of enhancing shareholder value.